Oramorph is a preparation containing morphine sulfate. The primary indication for using Oramorph is severe or persistent pain, particularly cancer-related pain, that does not respond to weaker analgesics.

Oramorph can be used in adults, adolescents, and children over the age of 1 year. It is available in the form of a solution and drops for oral administration. The liquid form allows for precise dose adjustment based on the patient’s age and weight.

Oramorph solution is available in a concentration of 2 mg/ml, in 100 ml bottles, while Oramorph drops are available in a concentration of 20 mg/ml, in 20 ml bottles.

Oramorph drops 20 mg/ml are included in the list of reimbursable medicines for the following indications*:

1. Chronic post-herpetic neuralgia; complex regional pain syndrome type I (reflex sympathetic dystrophy) and type II (causalgia) – with a 30% cost share for the patient.
2. Malignant tumors – free up to the limit.

Oramorph drops 20 mg/ml are also included in the list of free medications for the elderly over 65 years and for children under 18 years.

*Based on the decree of the Minister of Health regarding the list of reimbursable drugs, special medical purpose foods, and medical devices, in effect from April 1, 2024.